Navigation Links
Boston Scientific Announces Favorable Ruling in Patent Infringement Case
Date:1/23/2012

NATICK, Mass., Jan. 23, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces that the U.S. District Court for the District of New Jersey has found all the asserted patents in a suit brought by Johnson & Johnson to be invalid and entered judgment in favor of Boston Scientific.

As part of a 2008 suit, Johnson & Johnson alleged that Boston Scientific's PROMUS® Everolimus-Eluting Coronary Stent System infringed two patents, U.S. Patent Nos. 5,516,781 and 5,563,146 (known as "the Morris patents").  The patents relate to the use of a drug on a drug-eluting stent.

"We are pleased with the Court's finding that both of these Johnson & Johnson patents are invalid," said Tim Pratt, Executive Vice President, Chief Administrative Officer and General Counsel for Boston Scientific.  "Boston Scientific will continue to vigorously defend against any claims of infringement."

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties.  For more information, please visit: www.bostonscientific.com.  

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding litigation outcome and our product, litigation and risk management strategies.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. 

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial
2. nContacts Cardiac Ablation Technology to be Presented in Two Noteworthy Posters at Boston Atrial Fibrillation Symposium 2012
3. Boston Scientific Raises Awareness of Heart Disease at Brandon Jennings Invitational
4. Boston Scientifics Alair® Bronchial Thermoplasty System Achieves Important Reimbursement Milestones
5. Boston Scientific to Participate in 30th Annual J.P. Morgan Healthcare Conference
6. Boston Scientific Launches Charger™ PTA Balloon Catheter
7. Boston Scientific Receives FDA Approval for New Infinion™ 16 Percutaneous Lead for Precision Plus™ Spinal Cord Stimulator System
8. Boston Scientific Introduces Industry-Leading ICD and CRT-D Device Warranties
9. Boston Scientifics WATCHMAN® Device Implanted in First Patients in Latin America
10. Boston Scientific Applauds Introduction of Patient Access to Medical Innovation Act
11. Boston Scientific SYNERGY™ Stent Demonstrates Comparable Safety and Effectiveness Outcomes Versus PROMUS Element™ Platinum Chromium Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... April 28, 2016 ... George Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter ... heute bekannt, dass neue Führungskräfte zum Team ... sind, die vielfältige Erfahrungen mitbringen.  Dies wird ...
(Date:4/28/2016)... Treato , the single ... today that it has been named a Cool Vendor ... Life Sciences, 2016, Stephen Davies , ... on life-science- oriented analytics, algorithms and smart machine technology ... confirm medication ingestion, and analyze unstructured information.   ...
(Date:4/28/2016)... , April 28, 2016 Dr. ... and Ste phen ... ArisGlobal®, a leading provider of cloud-based software solutions for life ... Pharmacovigilance team to bring a wealth of insight to a growing ... pharmacovigilance knowledge. George Phillips joined ArisGlobal in ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... April 30, 2016 , ... ... Francis Talk Radio with Hypnotherapist, Mary O'Maley. What is hypnosis and hypnotherapy ... control (substances, smoking, weight control), pain relief (chronic and acute), birthing processes and ...
(Date:4/30/2016)... ... ... is a challenge for all of us, but there are things we can do to improve ... “Research is showing more and more that there are simple, yet important steps that can be ... Top priorities Dr. Kohli’s recommends for her patients include;, , exercise ...
(Date:4/29/2016)... ... April 29, 2016 , ... Since ... the national charitable foundation serving the footwear industry, has broken all previous participation ... than 130 companies across 23 states during the months of April and May, ...
(Date:4/29/2016)... ... April 29, 2016 , ... The American workforce is on ... security. Most importantly, employees are the single most important asset in creating value ... unhappy? , Just under half of American workers are emotionally checked out with ...
(Date:4/29/2016)... ... April 29, 2016 , ... A ... born with severe congenital diaphragmatic hernia have better survival rates if surgery is ... hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs ...
Breaking Medicine News(10 mins):